TRDA
Entrada Therapeutics, Inc.
Next earnings Aug 4, 2026 (before open) · consensus $-1.07 EPS, $420K rev
Last earnings -57.3% on 2026-05-07
$7.74
▲ +8.25%$7.74▲ +12.01%
over 1Y
L $5.09EODHDH $16.03
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+8.3%
1W+8.3%
1M+16.7%
3M-35.1%
YTD-23.0%
1Y+12.0%
Avoid
Conviction
Horizon
Medium (3–12mo)
Street · 14 analysts
Buy
Conservative balance sheet (liabilities/equity 0.23x); but revenue fell -87.9% YoY.
Revenue (FY2025) $25.4M · FY2025
Entrada Therapeutics, Inc. shows $25.4M in FY2025 revenue (-87.9% YoY), a -565.5% net margin, and -47.0% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | — | — | $129M | $211M | $25.4M |
| Gross profit | — | — | — | — | — |
| Operating income | -$51.1M | -$97.2M | -$3.16M | $47.0M | -$158M |
| Net income | -$51.2M | -$94.6M | -$6.68M | $65.6M | -$144M |
| Diluted EPS | -$8.16 | -$3.02 | -$0.20 | $1.68 | -$3.47 |
| Net margin | — | — | -5.2% | 31.1% | -565.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$206M
EV / EBITDA—
EV / Sales8.1
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-48.5%
FCF yield-43.7%
Quality & risk
ROIC (est.)-40.7%
Free cash flow-$130M
Total debt—
Net cash$90.4M
Altman Z-Score1.07 distress
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+1.8%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗8-KPeriod ending 2026-06-102026-06-10open ↗4Period ending 2026-05-202026-05-21open ↗8-KPeriod ending 2026-05-182026-05-19open ↗10-QPeriod ending 2026-03-312026-05-07open ↗8-KPeriod ending 2026-05-072026-05-07open ↗4Period ending 2026-05-042026-05-04open ↗
Frequently asked
- Is Entrada Therapeutics, Inc. (TRDA) a buy?
- TRDA currently carries a Avoid rating with 4/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity 0.23x); but revenue fell -87.9% YoY.
- What is Entrada Therapeutics, Inc.'s quality score?
- TRDA scores 35.23529411764706/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001689375, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 4:54:48 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.